LIXTE BIOTECHNOLOGY HOLDINGS

Company snapshot

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are cr

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 26 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LIXTE BIOTECHNOLOGY HOLDINGS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for LIXTE BIOTECHNOLOGY HOLDINGS.

1. Jun 8, 2026 Clinical update

   Dostarlimab — Phase 2

2. Jun 5, 2026 Clinical update

   LB-100 for Injection — Phase 1

3. May 23, 2026 Clinical update

   LB-100 — Phase 2

4. Jul 1, 2025 Patent grant

   Methods for treating soft tissue sarcoma

5. Mar 19, 2024 Patent grant

   Formulations of oxabicycloheptanes and oxabicycloheptenes

View all clinical trial activity →

• What is LIXTE BIOTECHNOLOGY HOLDINGS?

  Lixte Biotechnology Holdings is a biotech organization headquartered in East Setauket, USA. It trades on NYSE under ticker LIXT. Primary therapeutic focus areas include Ovarian Clear Cell Carcinoma, Tumors, Myelodysplastic Syndromes. NovaPharmaNews links 3 clinical program(s), 0

• Is LIXTE BIOTECHNOLOGY HOLDINGS publicly traded?

  Yes. LIXTE BIOTECHNOLOGY HOLDINGS is listed with ticker LIXT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does LIXTE BIOTECHNOLOGY HOLDINGS develop or market?

  We link 3 drug profile(s) where LIXTE BIOTECHNOLOGY HOLDINGS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lixte-biotechnology-holdings-inc#company-drugs.

• What are the latest developments for LIXTE BIOTECHNOLOGY HOLDINGS?

  In the last 12 months our linked public records show 3 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does LIXTE BIOTECHNOLOGY HOLDINGS focus on?

  LIXTE BIOTECHNOLOGY HOLDINGS focuses on Ovarian Clear Cell Carcinoma, Tumors, Myelodysplastic Syndromes based on our analysis of their pipeline programs and drug development activities.